open access

Vol 60, No 2 (2009)
Original papers
Published online: 2009-03-27
Submitted: 2013-02-15
Get Citation

Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis

Ewa Sewerynek, Katarzyna Dąbrowska, Elżbieta Skowrońska-Jóźwiak, Arkadiusz Zygmunt, Andrzej Lewiński
Endokrynologia Polska 2009;60(2):76-81.

open access

Vol 60, No 2 (2009)
Original papers
Published online: 2009-03-27
Submitted: 2013-02-15

Abstract


Introduction: It has been shown that more than 50% of people with a chronic disease, including osteoporosis, discontinue treatment during its first year. This problem increases with the time of observation. The aim of this study was to assess alendronate compliance over a period of 6 or 18 months in clinical practice of postmenopausal osteoporosis.
Material and methods: Using a retrospective study of clinical histories (357) obtained in our Outpatient Clinic, as well as telephone interviews with patients, the compliance with alendronate therapy in postmenopausal patients was assessed.
Results: After 1.5 years on observation 20.4% of patients, and after 0.5 years 8.5% of patients, discontinued their treatment as a result of intolerance (especially side effects on the gastrointestinal tract) (47.8%), health problems unrelated to osteoporosis (8.7%), inconvenience of the daily regimen (13.1%), costs (4.3%), and improvement of clinical condition (26.1%). It is worth mentioning that in both periods of observation (1.5 and 0.5 years) almost the same percentage of patient discontinued visits at our Outpatient Clinic (15.6% and 14.4%, respectively). Telephone interviews with patients who stopped attending the Outpatient Clinic at the Regional Centre of Menopause and Osteoporosis revealed that more than 50% of them discontinued the treatment.
Conclusions: Not all patients treated with alendronate are compliant. Osteoporosis is a chronic disease, which needs long clinical observation and constant adherence to medication. Effective communication between doctor and patient, and follow-up visits that are more frequent would greatly improve the adherence to osteoporosis treatment modalities. Compliant patients achieved increases in bone mass density with simultaneous fracture risk reduction.

Abstract


Introduction: It has been shown that more than 50% of people with a chronic disease, including osteoporosis, discontinue treatment during its first year. This problem increases with the time of observation. The aim of this study was to assess alendronate compliance over a period of 6 or 18 months in clinical practice of postmenopausal osteoporosis.
Material and methods: Using a retrospective study of clinical histories (357) obtained in our Outpatient Clinic, as well as telephone interviews with patients, the compliance with alendronate therapy in postmenopausal patients was assessed.
Results: After 1.5 years on observation 20.4% of patients, and after 0.5 years 8.5% of patients, discontinued their treatment as a result of intolerance (especially side effects on the gastrointestinal tract) (47.8%), health problems unrelated to osteoporosis (8.7%), inconvenience of the daily regimen (13.1%), costs (4.3%), and improvement of clinical condition (26.1%). It is worth mentioning that in both periods of observation (1.5 and 0.5 years) almost the same percentage of patient discontinued visits at our Outpatient Clinic (15.6% and 14.4%, respectively). Telephone interviews with patients who stopped attending the Outpatient Clinic at the Regional Centre of Menopause and Osteoporosis revealed that more than 50% of them discontinued the treatment.
Conclusions: Not all patients treated with alendronate are compliant. Osteoporosis is a chronic disease, which needs long clinical observation and constant adherence to medication. Effective communication between doctor and patient, and follow-up visits that are more frequent would greatly improve the adherence to osteoporosis treatment modalities. Compliant patients achieved increases in bone mass density with simultaneous fracture risk reduction.
Get Citation

Keywords

osteoporosis; compliance; alendronate 10; reasons for discontinuation

About this article
Title

Compliance with alendronate 10 treatment in elderly women with postmenopausal osteoporosis

Journal

Endokrynologia Polska

Issue

Vol 60, No 2 (2009)

Pages

76-81

Published online

2009-03-27

Bibliographic record

Endokrynologia Polska 2009;60(2):76-81.

Keywords

osteoporosis
compliance
alendronate 10
reasons for discontinuation

Authors

Ewa Sewerynek
Katarzyna Dąbrowska
Elżbieta Skowrońska-Jóźwiak
Arkadiusz Zygmunt
Andrzej Lewiński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl